A statistically significant higher plasma seroreactivity, >1.4-fold and up to 4.2-fold for Δ133p53γ, was found in individuals with premalignant lesions or CRC patients, respectively, in comparison with healthy individuals for p53γ, Δ40p53β, Δ40p53γ, Δ133p53γ, and Δ160p53γ p53 proteoforms, and for TAp63α, TAp63δ, ΔNp63α, and ΔNp63δ p63 proteoforms (Table 2). This evidence concerns the gene TP53 and colorectal carcinoma.